Name (Synonyms) | Correlation | |
---|---|---|
drug325 | CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test Wiki | 1.00 |
drug1292 | convalescent plasma application to SARS-CoV-2 infected patients Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.11 |
D007239 | Infection NIH | 0.07 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression. In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma. Only patients with moderate to severe disease at risk for transfer to intensive care unit or patients at the intensive care unit with limited treatment options will be treated.
Description: Serious adverse events during the study period include transfusion reaction (fever, rash), transfusion related acute lung injury (TRAU) , transfusion associated circulatory overload (TACO) , transfusion related infection
Measure: Serious adverse events in convalescent plasma treated patients Time: From baseline (enrolment) to 24 hours follow-upDescription: Change in SARS-CoV2 quantitative in nasopharyngeal swab
Measure: Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28Description: Transfer to ICU
Measure: Transfer to ICU Time: at Baseline (admission to Covid-ward) until day 28Description: in-hospital death
Measure: in-hospital death Time: at Baseline (admission to Covid-ward) until day 28Description: Change in SARS-CoV2 quantitative in plasma
Measure: Virologic clearance in plasma of convalescent plasma treated patients Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28Description: Duration of hospitalisation
Measure: Time to discharge from hospital after enrolment Time: at Baseline (admission to Covid-ward) until discharge (approx. 28 days)Description: Rise of SARS-CoV-2 antibody titers (on day 1, 7, 14 and 28)
Measure: Humoral immune response Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28